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Abstract 
Enhanced levels of the inflammatory chemokine CCL2 are known to correlate with increased 
tumorigenesis and metastases, and thereby poor prognosis for cancer patients. The CCL2-
CCR2 chemokine axis was shown to facilitate the metastatic initiation through the recruitment 
of inflammatory monocytes and the activation of endothelial cells at metastatic sites. Both 
steps are required for efficient cancer cell trans-endothelial migration and seeding in the 
targeted tissue. The translation of preclinical evidence proved to be challenging due to 
systemic effects of chemokine inhibition and limited target specificity. Here we tested an 
approach of a targeted delivery of the CCR2 antagonist Teijin Compound 1 to metastatic sites. 
VCAM-1 binding peptide tagged liposomes carrying the CCR2 antagonist enabled a specific 
delivery to cancer cell-activated endothelium. The subsequent binding of target-sensitive 
liposomes triggered the release of the Teijin Compound 1 and thereby local inhibition of 
CCR2 in the lungs. Blocking of CCR2 resulted in reduced induction of the lungs vascular 
permeability, and thereby reduced tumor cell extravasation. However, the recruitment of 
inflammatory monocytes to the pre-metastatic lungs remained unaltered. Endothelial VCAM-
1 targeted delivery of the CCR2 antagonist resulted in inhibition of pulmonary metastases 
both in a murine (MC-38GFP cells) and a human xenograft (patient-derived cells) model. 
Thus, timely- and spatially-defined inhibition of CCR2 signaling represents a potential 
therapeutic approach for treatment of metastasis without affecting homeostatic functions. 
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Introduction 
Chemokines are chemotactic cytokines that induce directed migration of cells to 
maintain homeostasis or to facilitate inflammatory processes. While the primary role of 
inflammatory chemokines is the recruitment of leukocytes to sites of inflammation, they also 
contribute to a variety of chronic inflammatory diseases and cancer. Inflammatory 
chemokines regulate a plethora of pathways involved in cancer progression and metastasis 
including: leukocyte recruitment, angiogenesis, survival and invasiveness of cancer cells, 
immune suppression, and cancer cell extravasation [reviewed in 1]. Particularly, higher levels 
of CCL2 have been linked to cancer progression, metastasis and poor cancer patient survival 
for several cancer types [2, 3]. In animal models, the CCL2-CCR2 chemokine axis was shown 
to have two essential roles during metastatic initiations: 1) recruitment of inflammatory 
monocytes to the pre-metastatic niche [4-6] and 2) activation of endothelial CCR2 required 
for induction of vascular permeability [6].  
Metastatic seeding of tumor cells in distant organs is usually associated with enhanced 
endothelial activation at the site of tumor cells [7]. Entrapped cancer cells in the vasculature 
have been shown to activate endothelial cells that express several activation markers, 
including VCAM-1 [7-9]. Furthermore, tumor cell extravasation mostly happens at these sites 
[8].  
While inflammatory chemokines have been considered to be promising therapeutic 
targets, their targeting revealed to be more difficult partly due to different chemokine 
involvement in specific diseases. For instance, in rheumatoid arthritis CCR2 has been 
identified to be a wrong target and rather CCR1 should be used as a target relevant for this 
condition [10, 11]. There is abundant preclinical evidence that CCL2-CCR2-axis targeting 
significantly affects cancer progression [4-6, 12, 13]. Accordingly, neutralization of CCL2 
was shown to be effective in preventing metastasis in numerous mouse models of cancer [e.g. 
4, 5]. However, recently it has been demonstrated that cessation of anti-CCL2 antibody 
treatment can lead to an increased metastatic burden in an orthotopic mammary tumor model 
using 4T1 cells [14]. The absence or the long-term inhibition of the CCL2-CCR2-axis 
significantly interferes with the homeostatic physiological processes, particularly the egress of 
inflammatory monocytes from the bone marrow [15, 16]. Thus, a targeted and timely defined 
inhibition of the chemokine signaling in the pre-metastatic niche would be highly beneficial to 
prevent metastatic initiation without any interference with homeostatic processes of CCL2-
CCR2 signaling. 
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To specifically inhibit CCL2 signaling at metastatic sites, we proposed to use a 
liposomal-carrier based approach to transport the CCR2 antagonist Teijin Compound 1 (TC1) 
to sites where cancer cells can activate the lung endothelium. TC1 was designed to inhibit 
binding of human CCL2 to CCR2b and to block the downstream signaling [17]. Nevertheless, 
the amino acids required for TC1 binding to CCR2 are conserved between human and mouse 
sequences [18]. VCAM-1 binding peptide tagged target-sensitive liposomes were previously 
shown to bind to activated endothelium of atherosclerotic aortas [19]. Here we demonstrate 
that VCAM-1 targeted delivery of liposomes loaded with the CCR2 antagonist TC1 to 
metastatic sites in the lungs reduces vascular permeability and prevents generation of 
pulmonary metastases. 
 
 
Materials and Methods 
Cell lines 
Patient-derived tumor material was injected in female immune-deficient NSG mice. A 
single cell suspension of in vivo passaged cells was obtained by tissue dissociation of 
xenograft tumors (P26) using Gentle-MACS (Miltenyi Biotec). The following cell lines were 
isolated and tested: human melanoma cells Mel_1956, colon carcinoma cells Co_9978, 
sarcoma cells Sar_10133 and mammary carcinoma cells Ma_4296. Mouse colon carcinoma 
cells, MC-38 stably expressing GFP (MC-38GFP), were grown as described previously [20]. 
Human endothelial cells, EA.hy926 line (ATCC) were grown in 10% FCS/DMEM medium as 
described previously [21]. Human monocytic cell line, U937 cells (a kind gift from Prof. S.C. 
Silverstein, Columbia University, New York, N.Y., USA), were grown in suspension in 5% 
FCS/RPMI culture medium. 
 
Trans-endothelial migration assay 
Mouse pulmonary endothelial cells were isolated from lungs using a positive immuno-
magnetic anti-CD31-antibody selection and cultivated in DMEM medium supplemented with 
20% FCS and with endothelial growth supplement as described previously [6]. Two weeks 
after isolation the primary endothelial cells were seeded on Boyden chamber inserts (8 μm 
pores, BD) and cultured until confluency. MC-38GFP cells were added into inserts with or 
without CD115+ bone-marrow derived monocytes (isolated by positive immune-magnetic 
selection using anti-CD115-biotin (eBioscience) in 3% FCS/RPMI medium. Transmigration 
was stimulated with 10% FCS/RPMI in the bottom of the Boyden chamber in the absence or 
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presence of a CCR2 antagonist = TC1 (20 μg/ml) or CCR5 antagonist = DAPTA (200 μg/ml), 
both inhibitors were obtained from R&D, and evaluated after 16 hours. Transmigrated MC-
38GFP cells were counted on the lower side of the insert. 
Human endothelial EA.hy926 cells were grown on Boyden chamber inserts (8 µm 
pores, BD) until confluency. Patient-derived melanoma cells Mel_1956 were added on the 
confluent endothelial cell layer with or without U937 monocytic cells in 1% FCS/DMEM/F12 
medium. Transmigration was stimulated with 10% FCS/DMEM/F12 in the bottom of the 
chamber in absence or presence of TC1 (20 µg/ml) or DAPTA (200 µg/µl). 
 
Liposomes 
The VCAM-1 binding peptide, sequence NH2-VHPKQHRGGSKGC-CO2 [22], was 
coupled to target-sensitive liposomes (TSL) composed of DOPE (1,2-dioleoyl-sn-gycero-3-
phosphoethanolamine), DOPA (1,2-dioleoyl-sn-glycero-3-phosphatidic acid), Mal-PEG-
DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene 
glycol)-2000]) as described previously [19]. Briefly, the phospholipids in chloroform were 
combined at the ratio of 65:35:2:3 mol % and dried in a rotary evaporator. Then, the lipid film 
was hydrated with PBS (empty TSL) or with a solution of CCR2 antagonist TC1 (TC1-TSL) 
at a drug: lipid ratio of 1:5, to reach the final lipid concentration of 10 mM. The resulting 
multilamellar vesicles were extruded through 100 nm polycarbonate membranes using a Mini-
Extruder (Avanti Polar Lipids, Alabaster, AL/USA). The VCAM-1 binding peptide, sequence 
NH2-VHPKQHRGGSKGC-COOH [22], was coupled at the surface of TSL by sulfhydryl-
maleimide chemistry as previously described [19]. To separate the uncoupled peptide and the 
non-incorporated TC1 from TSL, the Amicon centrifugal filter units with cut-off 100 kDa 
(Millipore) were used. Rhodamine-PE was added in a 1 mol% ratio to the liposome 
preparations to stain the TSL or non-TSL (liposomes without VCAM-1 binding peptide). 
 
Liposome targeting to activated endothelium in vivo 
All animal experiments were performed according to the guidelines of the Swiss 
Animal Protection Law, and approved by Veterinary Office of Kanton Zurich. Mice (n = 3) 
were intravenously injected (i.v.) with 3×105 MC-38GFP cells. After 16 hours, lungs were 
perfused through cardiac injection with 2 μmol TSL-Rhodamine-PE or 2 μmol non-TSL-
Rhodamine-PE in 5 ml PBS. After 15 min incubation, lungs were washed with PBS, fixed 
with 3% paraformaldehyde/PBS and embedded in OCT (Tissue-Tek). Cryosections (8 μm) 
were stained with anti-VCAM-1 antibody (BD), goat-anti-rat IgG (H+L) Alexa Fluor 680 
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(Invitrogen), and counterstained with DAPI. Stained sections were analyzed with a Leica SP5 
confocal microscope. 
 
Experimental metastasis 
Mice were intravenously treated either with 70 μg TC1 in 150 μl 5% glucose/H2O, 150 
μl TC1-TSL (0.79 μmol lipid encapsulating 52 μg TC1), or 150 μl empty-TSL (0.79 µmol 
lipid) one hour before and 16 hours after i.v. injection of 3×105 MC-38GFP cells. Mice were 
terminated after four weeks. Lungs were perfused with PBS and the number of metastatic foci 
per lung was determined macroscopically.  
Human melanoma cells Mel_1956 (5×105) were i.v. injected into the tail vein of each 
mouse. Mice were i.v. treated with 4 mg TC1/kg (corresponding to 80µg/20g mouse) in free 
or liposomal form 4 hours before and at the time of tumor cell injection, followed by further 
injections of the same dose at 4 and 24 hours after tumor cell injection. Empty-TSL was 
injected at a corresponding lipid dose at the same time. After 14 days mice were terminated, 
macroscopically inspected by autopsy and the number of metastatic foci was counted. 
 
Flow cytometry analysis of peripheral blood 
Blood samples (80 µl) were taken sublingually, diluted with 2 ml of 5mM EDTA in 
PBS (EDTA/PBS), and centrifuged for 5 min at 500 g. To lyse erythrocytes, cells were 
resuspended in 1 ml PharmLyse (BD) and incubated for 15 min at room temperature. Cells 
were centrifuged for 5 min at 500 g and resuspended in FACS buffer (10mM EDTA, 2% 
FCS, in PBS) and stained with CD11b-APC-Cy7, Ly6G-PerCP-Cy5.5, Ly6C-FITC, CD8-PE-
Cy7 (all from BD) for 30 min on ice. The cells were washed once with 1 ml PBS and then 
acquired with a FACSCanto (BD) machine. The results were analyzed by FlowJo software 
(Tree star). 
 
Flow cytometry analysis of lungs 
Mice were treated with 70 μg TC1 in 150 μl 5% glucose/H2O, 150 μl TC1-TSL (0.79 
μmol lipid encapsulating 52 μg TC1), or 150 μl empty-TSL (0.79 µmol lipid) 10 min prior to 
i.v. injection of 3×105 MC-38GFP cells. After 12 hours, lungs were perfused with PBS and 
digested for 1 hour with collagenase A and collagenase D (each 2mg/ml, Roche) in 2% 
FCS/RPMI1640 at 37°C. Cells were filtered through a 100 μm cell strainer (BD) and stained 
with LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit (Life Technologies) followed by 
staining with: anti-CD45-PE-Cy7, anti-CD11b-APC, anti-Ly6G-PerCP-Cy5.5, anti-Ly6C-
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FITC antibodies. Data were acquired in the presence of CountBright absolute counting beads 
(Life Technologies) with a FACSCanto machine (BD) and analyzed by FlowJo software 
(Tree star). 
 
Vascular permeability assay (Evans blue assay) 
Mice were treated with 150 μl TC1-TSL (0.79 μmol lipid encapsulating 52 μg TC1), 
or 150 μl empty-TSL (0.79 µmol lipid) 10 min prior to i.v. injection of 3×105 MC-38GFP 
cells. After 24 hours mice were intravenously injected with 2 mg of Evans blue in 100 μl 
PBS. The lungs of mice were perfused 30 min later, pictures taken and homogenized in PBS. 
The Evans blue dye was extracted with formamide at 60°C for 18 hours. The amount of 
extravasated Evans blue was determined by spectrophotometry (absorbance at 620 nm).   
 
Cytometric bead array determination of CCL2 
The concentration of hCCL2 in cell-culture supernatants of human cancer cells was 
determined with the CBA Human MCP-1 Flex Set (BD) according to the manufacturer’s 
instructions. Briefly, 50 μl of pure or 1:10 diluted cell culture supernatants were incubated 
with hCCL2 capture beads and hCCL2-PE detection reagent (total reaction volume of 150 μl) 
for three hours at room temperature, and washed once with 1 ml of the supplied Wash Buffer. 
The beads were reconstituted with 200 μl Wash Buffer and then acquired with a FACSCanto 
(BD) machine. The mean fluorescent intensity (MFI) of the sample-beads was used to 
calculate the concentration of hCCL2 in the samples according to the standard-curve of 
hCCL2. 
 
Statistical analysis  
Statistical analysis was performed with the GraphPad Prism software (version 5.0). Data are 
presented as mean ± SEM and data with more than 2 groups were analyzed using ANOVA 
test with Bonferroni’s multiple comparison, unless stated otherwise. 
 
Results 
TC1 inhibits cancer cell trans-endothelial migration 
The CCR2 antagonist Teijin Compound 1 (TC1) was developed to target human 
CCR2 activation and consequently, to inhibit the ensuing cell chemotaxis induced by CCL2 
[23]. However, human and mouse CCR2 have the same amino acid sequence required for 
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TC1 binding [18]. To validate the capacity of TC1 to inhibit murine CCR2, we used the trans-
endothelial tumor cell migration experiment employing primary pulmonary endothelial cells. 
We used mouse colon carcinoma cell line MC-38GFP, which was previously shown to 
produce CCL2 that is critical for metastatic seeding [6]. The addition of CD115+ monocytes 
accelerated the transmigration of MC-38GFP cells compared to tumor cells without 
monocytes. We found a strong inhibition of tumor cell migration in the presence of TC1 
(Figure 1). However, the addition of DAPTA, a CCR5 antagonist, did not affect trans-
endothelial migration of MC-38GFP cells. These data confirm that TC1 can inhibit CCR2 in a 
murine model. 
 
 
VCAM-1 binding peptide enables efficient targeting of liposomes to activated 
endothelium 
We hypothesized that the low molecular mass (476 Da) of TC1 would cause fast 
clearance from circulation and thereby prevent an inhibitory effect on CCR2-based processes 
in vivo. Therefore, we prepared target-sensitive liposomes (TSL) coupled to a VCAM-1 
binding peptide and loaded them with TC1 (TC1-TSL). The binding and TC1 release 
characteristics of VCAM-1 binding liposomes have been recently described [19]. VCAM-1 
was detected on activated endothelium during metastasis [7, 9]. To test the specific targeting 
in a metastatic mouse model, we perfused mice, which received i.v. injection of MC-38GFP 
cells 16 hours earlier, with Rhodamine-PE labeled TSL or non-TSL (without VCAM-1 
binding peptide). VCAM-1 expression in the pulmonary vasculature has been detected 
between 12-18 hours post-tumor cell injections [7]. Indeed, the presence of VCAM-1 binding 
peptide on the liposomes ensured strong binding of the TSL to the vasculature in the 
proximity of MC-38GFP cells, while binding of non-TSL to the activated endothelium could 
not be detected (Figure 2). We observed no uptake of TSL in the lungs of control mice, while 
accumulation of TSL has been detected in the liver after 2 h (data not shown). These data 
Figure 1. Transmigration of tumor cells across 
primary murine pulmonary endothelial cells is 
inhibited by TC1. Trans-endothelial migration of 
MC-38GFP tumor cells through endothelial 
monolayers in the presence or in the absence of 
monocytes. CCR2 inhibitor TC1 (20 μg/ml) and 
CCR5 inhibitor DAPTA (200 μg/ml) were added 
to the co-culture. Transmigrated tumor cells were 
counted per view field and are presented in 
relative values. Pooled data from three individual 
experiments are presented ***, P < 0.001. 
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support the specificity of the VCAM-1 binding peptide for the activated endothelium and the 
ability to selectively target liposomes to the activated vasculature in vivo.  
 
 
 
 
 
TC1-TSL inhibit pulmonary seeding of metastatic cancer cells 
CCR2-mediated interactions have been shown to be required for initiation of 
metastasis, particularly in the lung tissues [4-6, 24]. To test whether TC1-TSL targeting to the 
pre-metastatic niche affect metastatic seeding, we used a lung experimental metastasis model 
with MC-38GFP cells. We aimed to inhibit CCR2 signaling during the whole time when 
tumor cells are in circulation [6], thus it does not completely mimic the clinical situation. 
Mice receiving TC1-TSL had significantly reduced metastasis when compared to control mice 
receiving no treatment or mice treated with TC1 loaded non-TSL (Figure 3). As expected 
mice treatment with soluble TC1 had no effect on metastasis. However, empty-TSL still had a 
significant reduction in the number of metastasis when compared to control mice. This is 
likely due to VCAM-1-directed TSL occupation of activated endothelium, which could impair 
monocyte function. While monocytes in circulation are required for metastasis [5, 6], their 
reduction significantly affects metastasis [25, 26]. Nevertheless, targeted delivery of TC1 
using TC1-TSL significantly reduced the incidence of metastasis when compared to empty-
TSL (Figure 3B), which further supports the role of CCR2 during metastatic seeding to the 
lungs. 
Figure 2. VCAM-1 binding peptide 
facilitates efficient targeting of 
TSL to activated endothelium in 
lungs. Mice received intravenous 
injection of MC-38GFP cells 16 
hours prior perfusion with either 
Rhodamine-PE-TSL or Rhodamine-
PE-non-TSL. Red: liposomes; white: 
VCAM-1 staining; green: MC-
38GFP cells, blue: DAPI. Bar = 30 
µm. 
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Figure 3. TC1-TSL attenuates experimental pulmonary metastasis. A) Mice were treated 1 hour 
before and 16 hours after i.v. MC-38GFP injection with TC1-TSL, empty-TSL, TC1 non-TSL or free 
TC1. B) Four weeks later, mice were terminated and metastatic foci were counted macroscopically. *, 
P < 0.05; **, P < 0.01; ***, P < 0.001. C) Representative pictures of metastatic lungs. Bar = 5 mm. 
 
Liposome treatment reduces circulating inflammatory monocytes but their recruitment 
to metastatic lungs remains unaffected 
To test whether liposome treatment affects monocytic population in the circulation, we 
analyzed peripheral blood of treated mice 24 hours after MC-38GFP cell injection. Both 
liposome preparations TC1-TSL and empty-TSL respectively, equally reduced the number of 
circulating Ly6Chi inflammatory monocytes when compared to control mice (Figure 4A). TC1 
treatment alone had no effect on the presence of Ly6Chi inflammatory monocytes in 
circulation. These data indicate that TSL have an intrinsic activity leading to partial depletion 
of circulating monocytes, which requires further investigations. 
The presence of cancer cells in the lungs was shown to induce immediate recruitment 
of inflammatory monocytes (Ly6Chi) to the metastatic microenvironment, which promotes 
tumor cell extravasation and metastasis [5, 6]. Next we assessed whether liposome treatment 
affects the leukocyte recruitment to the lungs of MC-38GFP injected mice. As expected 
intravenous injection of MC-38GFP cells induced rapid increase of Ly6Chi inflammatory 
monocytes in the lung tissue compared to lungs of naive mice (Figure 4B). But, mice treated 
with empty-TSL, TC1-TSL, or TC1 alone have shown a similar increase in numbers of 
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Ly6Chi inflammatory monocytes in the lungs. These results indicate that TC1-TSL treatment 
did not significantly impair the global recruitment of monocytic cells to the early metastatic 
lungs and thus reduces metastasis by acting locally at metastatic sites.  
 
 
 
Figure 4. Liposome treatment affects inflammatory monocytes and lungs vascular leakiness. A) 
Blood was taken from control mice or mice treated with empty-TSL, TC1-TSL, or TC1 20 hours after 
MC-38GFP injection (4 hours after the second liposome injection) and analyzed by flow cytometry. 
The CD11b+Ly6Chi cells were standardized to the number of CD8+ cells (1’000 cells). B) Control mice 
or mice treated with empty-TSL, TC1-TSL, or TC1 were terminated 12 hours after MC-38GFP 
injection. The leukocyte composition in the perfused lungs was analyzed by flow cytometry and the 
effective number of inflammatory monocytes (CD45+CD11b+Ly6ChiLy6G-) per lungs is presented. C) 
Empty-TSL- or TC1-TSL-treated mice were intravenously injected with Evans blue 24 hours after 
tumor cell injection. Naive mice (without tumor cell injection) were injected with Evans blue and used 
as a control. The amount of extracted Evans blue from lung tissue was measured by 
spectrophotometry. Data were analyzed using Mann-Whitney test **, P < 0.01. D) Representative 
macroscopic images of lungs from Evans blue injected mice. 
 
 
TC1-TSL treatment reduces lung vascular permeability in tumor cell injected mice 
Previously, we have shown that inhibition of CCR2 affects the tumor cell 
extravasation in the lungs, which is partially mediated by endothelial CCR2 signaling [6]. 
Since we observed no reduction of inflammatory monocytes in the metastatic lungs of treated 
and control mice, we tested whether lung vascular permeability is impaired in TC1-TSL 
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treated mice. Mice injected with TC1-TSL or empty-TSL, and MC-38GFP cells were 
intravenously injected with Evans blue 24 hours later. We detected a significant reduction in 
vascular permeability of TC1-TSL treated mice when compared to empty-TSL injected mice 
(Figure 4C). These data are in agreement with the detection of TSL in the proximity of tumor 
cells and the concomitant endothelial activation (Figure 2). They further indicate that the local 
release of TC1 is sufficient for blocking tumor cell extravasation, and thereby the metastatic 
initiation.  
 
TC1 inhibits trans-endothelial migration of patient-derived tumor cells expressing 
CCL2  
Increased levels of CCL2 chemokine have been associated with a poor outcome and 
shorter disease-free survival due to high incidence of metastasis in patients with breast, colon, 
prostate, and cervical cancer [1]. We tested the CCL2 release of four different tumor cells 
derived from cancer patients. We detected different CCL2 levels varying from 13.6 to 7181 
pg/ml depending on cancer type (Table 1). These data correspond well with previously 
detected CCL2 levels in the serum of breast and colon cancer patients [2, 3].  
 
Table 1. CCL2 protein levels detected in medium of cancer cells derived from patients. The cells 
were grown in cell culture for two days and the protein amount of CCL2 in the medium was 
determined using the CBA assay. Average (± SD) of at least 3 independent samples is presented. 
Patients derived cancer cells hCCL2 (pg/ml) 
Colorectal cancer cells_9978  25.7 ± 1.3 
Mammary cancer cells_4296 13.6 ± 6.5 
Sarcoma cells_10133 7881.7 ± 2467.6 
Melanoma cells_1956 95.9 ± 32.7 
 
Next we tested the capacity of TC1 to inhibit trans-endothelial migration of patient-
derived tumor cells using the Boyden chamber assay. We selected melanoma cells Mel_1956, 
which produce significant but not too high amounts of CCL2, thus we can block its activity. 
While monocytes potentiated trans-endothelial migration of Mel_1956 cells, TC1 clearly 
inhibited this process (Figure 5A). The presence of the CCR5 inhibitor DAPTA had no impact 
on Mel_1956 cell trans-endothelial migration. These data confirm that inhibition of CCR2 
impedes the efficient trans-endothelial migration of human tumor cells as was shown also for 
the mouse cell line MC-38GFP (Figure 1).  
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Figure 5. TC1 inhibits trans-endothelial migration and metastasis of human melanoma cells. A) 
Migration of human Mel_1956 melanoma cells across human endothelial monolayers in the presence 
or in the absence of U937 monocytic cells. CCR2 inhibitor TC1 (20 μg/ml) and CCR5 inhibitor 
DAPTA (200 μg/ml) were added to the assay. Transmigrated tumor cells were counted per view field 
after 16 hours and are presented in relative values. ***, P < 0.001.  B) Female NSG mice were i.v. 
injected with Mel_1956 cells. Mice were treated 4 hours before, at the time of tumor cell injection, and 
4 and 24 hours after tumor cell injection with TC1, TC1-TSL, empty-TSL or PBS (control). Mice 
were terminated after 14 days and metastatic foci were counted. ** = P < 0.01; n.s. = not significant. 
Data are presented as mean ± SEM. C) Number of mice per group with (black) and without (white) 
metastasis.  
 
 
TC1-TSL inhibit pulmonary seeding of metastatic human cancer cells 
To test whether CCR2 inhibition also affects the engraftment of human cancer cells in 
vivo, we used human melanoma cells Mel_1956 derived from a patient in an immune-
deficient mouse model. Mice were sacrificed and macroscopically inspected two weeks after 
i.v. injection of Mel_1956 cells. First we evaluated the incidence of metastasis. In the control 
group, 9 of 10 mice developed metastases, while the treatment with TC1 reduced that number 
to 6 of 8 (75%). The treatment with liposomes further reduced the number of metastases per 
mouse as well as the number of mice found with metastases to 4 of 8 (50%) and 1 of 8 
(12.5%) for mice treated with empty-TSL and TC1-TSL, respectively. The number of 
metastases found in the TC1-TSL treated group was significantly reduced in comparison to 
the control group (Figure 5B), while empty-TSL or TC1 alone did not reduce the number of 
metastases significantly. These data support the finding that TC1 targeting with TSL reduces 
metastasis also in a xenograft model.   
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Discussion 
Metastases are responsible for about 90% of all cancer related fatalities [27] and the 
lungs are one of the organs affected in many cancers. Although initiation of metastasis can 
occur early during tumorigenesis, there is evidence that the surgical removal of the primary 
tumor and the associated inflammation correlates with enhanced metastasis [28]. Furthermore, 
the surgery is associated with an increase in circulating tumor cells, which enhances their 
potential to form metastatic lesion. Tumor cells in the vasculature are highly vulnerable yet 
accessible for any treatment, and therapeutic efficiency is expected to be the highest during 
this stage [29, 30]. Therefore an adjuvant treatment aiming at potential metastatic tumor cells 
prior to extravasation may improve the long-term cancer therapy. The mechanism of 
metastatic initiation is strongly linked to the activation of the CCL2-CCR2 chemokine axis [4-
6]. Apparently CCR2-mediated signaling is involved at two levels: 1) recruitment of 
inflammatory monocytes to the pre-metastatic niche and 2) activation of endothelial CCR2 
and thereby the induction of vascular permeability. We expect that the inhibition of the 
CCL2-CCR2 signaling axis during metastatic initiation will inhibit tumor cell extravasation 
and subsequently metastases. We provided evidence that the monocyte-mediated trans-
endothelial migration of both murine colorectal cancer cells and human melanoma cells in 
vitro is specifically inhibited by the CCR2 antagonist TC1. These results support the 
functional role of CCR2 signaling in the cross-talk among tumor cells, monocytes, and 
endothelial cells in this process. Since CCL2-CCR2 signaling has no effect on the recruitment 
of monocytes in this in vitro system, we speculate that CCR2 inhibition predominantly affects 
endothelial cells. This is supported by previous findings that endothelial- rather than 
monocytic-CCR2 expression is required for the tumor cell trans-endothelial migration [6]. 
While the CCR2-mediated recruitment of inflammatory monocytes clearly contributes to 
metastatic initiation [5, 6], we reason that endothelial CCR2 might be the main regulator of 
vascular permeability induction and cancer cell extravasation [6, 24]. This hypothesis is 
supported by the fact that the TC1-TSL treatment did not reduce the recruitment of 
inflammatory monocytes to the lungs of MC-38GFP injected mice, yet clearly attenuated 
metastasis. Importantly, the induction of pulmonary vascular permeability was reduced in 
TC1-TSL compared to empty-TSL treated cancer cell injected mice. These results indicate 
that local interference in the lung CCR2 signaling is sufficient for attenuation of metastasis. 
The idea of targeted drug delivery to desired tissues is not new. However, the 
application of a specific liposomal composition, which is triggered by target-binding for 
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controlled destabilization and thus drug release, has not been applied for anti-metastatic 
approaches. We have used TSL as the carrier for delivering TC1 to sites of tumor cell-
activated endothelium. TSL binding to VCAM-1 expressed on the activated endothelium 
destabilizes liposomes and releases their cargo [19, 31]. We showed that TSL-targeting to 
tumor cell-activated pulmonary endothelium was successful which is in line with previous 
observations where TSL targeting to the atherosclerotic plaques, expressing VCAM-1, has 
been performed [19]. Administration of TSL however, caused a depletion of circulating 
inflammatory monocytes, which was independent of the TC1 presence. Depletion of 
circulating inflammatory monocytes by clodronate-loaded liposomes was previously shown to 
severely affect pulmonary seeding of tumor cells [25]. It is thus likely that the liposome 
composition is partially responsible for this phenomenon, and consequently for a direct or 
indirect reduction of experimental metastatic foci numbers in both groups (empty-TSL and 
TC1-TSL) when compared to controls. Nevertheless, TC1-TSL significantly reduced 
metastatic seeding when compared to empty-TSL, indicating that the targeted delivery of 
CCR2 antagonist to the metastatic tissue (lungs) almost abolished generation of metastases.  
Tumor cell extravasation and thereby seeding of distant tissues happens at sites of the 
activated endothelium [8]. Our targeted approach confirms that selective inhibition of CCR2 
signaling at these sites of metastatic initiation prevents generation of metastases. Contrary, 
systemic inhibition of the CCR2 signaling in the same time frame did not have any effect on 
the generation of metastases (TC1 treated mice). This is likely also due to the faster clearance 
of the compound. Collectively these results show that the temporally and spatially defined 
inhibition of CCR2 signaling can prevent the generation of metastasis by mainly interfering 
with induction of pulmonary vascular permeability required for cancer cell extravasation [6, 
24].  
CCL2 has been previously targeted in various pathophysiological models, e.g. 
metastasis and liver damage [5, 32]. Antibody-mediated depletion of CCL2 led to reduced 
infiltration of macrophages to metastatic sites [5], while the use of pharmacological inhibitor 
to CCL2 reduced macrophages-dependent angiogenesis during liver fibrosis [32]. However, a 
long-term neutralization of CCL2 by antibody treatment caused a significant depletion of 
circulating monocytes, which was primarily due to the inhibition of monocyte egress from the 
bone marrow [14]. A timely defined CCR2 inhibition is unlikely to interfere with global 
homeostatic roles of CCL2-CCR2 signaling, which affects the levels of circulating 
inflammatory monocytes [15]. The presented treatment strategy enables an increased 
therapeutic efficiency due to presence of a high local concentration of the inhibitor at required 
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sites, while keeping other tissues unaffected. However, the further development of alternative 
nanocarriers would be required for evaluation beyond animal models. 
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